Search

Veracyte Inc

Open

SectorHealthcare

41.21 -3.04

Overview

Share price change

24h

Current

Min

40.98

Max

43.6

Key metrics

By Trading Economics

Income

-3.2M

25M

Sales

11M

150M

P/E

Sector Avg

33.774

57.002

EPS

0.37

Profit margin

16.957

Employees

755

EBITDA

-11M

24M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+35.56% upside

Dividends

By Acuity

Next Earnings

3 lis 2026

Market Stats

By TradingEconomics

Market Cap

-718M

3.7B

Previous open

44.25

Previous close

41.21

News Sentiment

By Acuity

50%

50%

171 / 340 Ranking in Healthcare

Veracyte Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 sie 2026, 19:51 UTC

Veracyte Inc shares are lower today, breaking a trend of higher closes. No specific news was identified for this decline amid notable market volume.

12 sie 2026, 20:01 UTC

Veracyte Inc shares are lower today, following a broader market decline. The stock remains significantly below its 20-day moving average.

11 sie 2026, 19:26 UTC

News

Veracyte Inc reported second-quarter revenue of $150.32 million and raised its 2026 outlook to $590 million to $596 million, boosting shares higher.

10 sie 2026, 19:36 UTC

News

Veracyte Inc shares declined Monday, trading lower since Friday's close amid broader market volatility and rising oil prices affecting inflation expectations.

7 sie 2026, 19:26 UTC

Correlated Moves

Veracyte Inc shares are higher, supported by a rise in the ARK Genomic Revolution ETF and broader small-cap strength from the Russell 2000 Index.

6 sie 2026, 19:26 UTC

Veracyte Inc shares are higher today, despite earlier losses. No specific news was identified to explain the price movement during the session.

5 sie 2026, 19:32 UTC

Veracyte Inc's shares are lower, reflecting broader market sentiment amid recent crude oil price declines. Trading volume is unusually high today.

4 sie 2026, 19:36 UTC

News
Correlated Moves

Veracyte shares are rising as Piper Sandler and Stephens maintain Overweight ratings, despite lowering price targets to $54 and $55, respectively.

3 sie 2026, 20:06 UTC

Veracyte Inc's shares are lower today, diverging from broader market gains amid high trading volume. No specific news was identified to explain the decline.

1 sie 2026, 00:01 UTC

Veracyte Inc is trading lower in after-market hours, reflecting broader market declines. Shares remain near the lower end of their one-month range.

31 lip 2026, 20:02 UTC

News
Social Media

Veracyte Inc shares are lower despite positive analyst outlooks and target increases from Freedom and Needham following a recent earnings report that exceeded expectations.

30 lip 2026, 23:21 UTC

News
Social Media

Veracyte shares fell in after-market trading despite reporting second-quarter revenue of $150.3 million and adjusted EPS of $0.54, exceeding expectations.

29 lip 2026, 19:47 UTC

Macro Event

Veracyte Inc's shares are advancing as the Federal Reserve maintains interest rates. The decision aligns with market expectations amid ongoing economic expansion.

28 lip 2026, 15:22 UTC

Veracyte Inc. shares are higher today, supported by broader strength in biotechnology stocks. No specific news was identified to explain the price movement.

27 lip 2026, 20:14 UTC

Veracyte Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment may be affected by declining crude oil prices.

24 lip 2026, 22:16 UTC

Correlated Moves

Veracyte Inc shares declined during after-market hours, reflecting broader weakness in the biotechnology sector. The stock shifted toward the lower end of its one-month trading range.

22 lip 2026, 20:13 UTC

Correlated Moves

Veracyte Inc shares are lower in after-market trading, reflecting broader market declines amid rising crude oil prices and geopolitical tensions.

21 lip 2026, 17:16 UTC

Correlated Moves

Veracyte Inc shares are higher today, recovering after three days of declines. The stock is now above its 20-day moving average.

20 lip 2026, 20:01 UTC

Correlated Moves

Veracyte Inc shares declined sharply today, marking three consecutive lower sessions amid broader market weakness and heightened volatility related to geopolitical tensions.

Peer Comparison

Price change

Veracyte Inc Forecast

Price Target

By TipRanks

35.56% upside

12 Months Forecast

Average 57.75 USD  35.56%

High 70 USD

Low 44 USD

Based on 10 Wall Street analysts offering 12 month price targets forVeracyte Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

8

Buy

1

Hold

1

Sell

Sentiment

By Acuity

171 / 340 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
help-icon Live chat